Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lefrex is a branded generic antibiotic containing levofloxacin, a third-generation fluoroquinolone. Marketed by SBM Enterprises (also known as SBM Pharmaceuticals) in India, it is typically available as a 500 mg oral tablet. Levofloxacin is a broad-spectrum antibacterial agent that works by inhibiting the bacterial enzymes DNA gyrase (topoisomerase II) and topoisomerase IV. These enzymes are critical for bacterial DNA replication, transcription, repair, and recombination; their inhibition leads to bacterial cell death. Lefrex is indicated for the treatment of various bacterial infections, including community-acquired pneumonia, urinary tract infections, skin and soft tissue infections, and infections of the ear, nose, and throat.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Lefrex.